Healthcare solutions provider Molbio Diagnostics raised $85 million in funds from Singapore-based investment firm Temasek.
Molbio Diagnostics is well-known for its ‘Truenat’ technology, which is a portable, battery-powered real-time PCR platform for testing infectious diseases such as tuberculosis, COVID-19, Hepatitis-C virus, human papillomavirus, influenza, and vector-borne diseases such as dengue, chikungunya, and malaria. Temasek’s new funds, along with those from existing investors like Motilal Oswal Alternates, will assist the company in accelerating the development and commercialization of new technologies based on clinical need gaps. This will also aid the company’s efforts to bring the Truenat platform to global markets.
